湖南方盛制药股份有限公司 HUNANFANGSHENG PHARMACEUTICAL CO., LTD. 证券代码：603998 证券简称：方盛制药 公告编号：2023-073 湖南方盛制药股份有限公司 关于股权激励限制性股票回购注销实施公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述 或者重大遗漏，并对其内容的真实性、准确性和完整性承担法律责任。 重要内容提示： 回购注销原因：因5名首次授予的激励对象离职、4名预留部分授予的激励对象 离职、48名首次授予的激励对象业绩考核结果未满足100%解禁要求，根据《方盛制药2022 年限制性股票激励计划（草案）》（以下简称"《激励计划》"）的相关规定，湖南方 盛制药股份有限公司（以下简称"公司"或"方盛制药"）对其已获授但尚未解除限售 的相应限制性股票予以回购注销，需回购注销股份数合计为551,500股。 一、本次限制性股票回购注销的决策与信息披露 1、2022年5月19日，公司召开2021年年度股东大会审议通过 了《关于提请股东大会授权董事会办理湖南方盛制药股份有限公 司2022年限制性股票激励计划有关事项的议案》，授权董事会全 权办理《激励 ...

2023 年第三次临时股东大会 会议资料 中国湖南 长沙 2023 年 9 月 19 日 湖南方盛制药股份有限公司 HUNANFANGSHENG PHARMACEUTICAL CO., LTD. 目 录 | 2023 | 年第三次临时股东大会会议议程 | 3 | | --- | --- | --- | | 2023 | 年第三次临时股东大会会议须知 | 5 | | 议案 | 1：关于公司 2023 年半年度利润分配方案的预案 | 6 | | 议案 | 2：关于补选公司独立董事的议案 | 7 | 第 2 页，共 7 页 湖南方盛制药股份有限公司 HUNANFANGSHENG PHARMACEUTICAL CO., LTD. 2023 年第三次临时股东大会会议议程 会议时间：2023 年 9 月 19 日下午 14:30 会议地点：公司办公大楼一楼会议室（一）（长沙市国家高新技术产业开发 区嘉运路 299 号） 会议召集人：公司董事会 大会主持人：董事长周晓莉女士 大会议程： ★ 签到、宣布会议开始 一、与会人员签到，领取会议资料；股东及股东代理人同时提交身份证明材 料（授权委托书、营业执照复印件、身份证复印件等 ...

Financial Performance - The company's operating revenue for the first half of 2023 was approximately RMB 855.22 million, a decrease of 2.07% compared to the same period last year [23]. - Net profit attributable to shareholders of the listed company reached approximately RMB 106.71 million, representing a significant increase of 68.86% year-on-year [23]. - The net profit after deducting non-recurring gains and losses was approximately RMB 87.49 million, an increase of 118.90% compared to the previous year [23]. - The company reported a net cash flow from operating activities of approximately -RMB 54.86 million, a decline from RMB 75.48 million in the same period last year [25]. - Total assets increased by 4.07% to approximately RMB 3.04 billion compared to the end of the previous year [25]. - Basic earnings per share for the first half of 2023 were RMB 0.25, up 66.67% from RMB 0.15 in the same period last year [25]. - The weighted average return on net assets increased by 2.24 percentage points to 7.39% compared to the previous year [25]. - The company achieved a 14.84% year-on-year growth in pharmaceutical industrial revenue, driven by enhanced product promotion and market expansion [25]. - The company has excluded the loss-making subsidiary Baijun Medical from its consolidated financial statements, which contributed to the increase in net profit [25]. - The company achieved a half-year sales revenue exceeding 100 million yuan and a net profit of over 27 million yuan, marking a significant milestone in performance [59]. Dividend and Shareholder Information - The company plans to distribute a cash dividend of 0.90 CNY per 10 shares to all shareholders on the record date, pending approval at the shareholders' meeting [5]. - The company has not proposed any capital reserve transfer to increase share capital in the profit distribution plan [5]. - The total number of shares increased by 849,000, resulting in a new total of 440,451,120 shares, with the proportion of limited sale shares rising from 2.31% to 2.50% [150]. - The company repurchased and canceled 296,000 shares of restricted stock from the 2022 incentive plan, with the cancellation completed on February 8, 2023 [151]. - A total of 1,145,000 shares of restricted stock were granted to 24 individuals, with a grant price of 2.91 yuan per share, completed on February 27, 2023 [152]. Risks and Challenges - The company has outlined various risks it may face in its operations, detailed in the management discussion and analysis section [8]. - The company faces risks from intensified market competition, with a focus on maintaining product quality and establishing a long-term quality management system [79][80]. - The establishment of a national procurement office for traditional Chinese medicine indicates a shift to nationwide procurement, leading to potential price declines for products, which may impact revenue [82]. - In the first half of 2023, the prices of traditional Chinese medicinal materials showed an upward trend, which could adversely affect the company's cost structure [82]. - The company is actively managing safety stock levels and establishing strategic reserves for key raw materials to mitigate supply risks [82]. Environmental Management - The company is classified as a key pollutant discharge unit in Changsha, with annual discharge limits for COD at 10.55 tons, ammonia nitrogen at 0.928 tons, sulfur dioxide at 0.161 tons, and nitrogen oxides at 4.032 tons [1]. - The company upgraded its wastewater treatment process to include iron-carbon micro-electrolysis, flotation, UASB anaerobic treatment, and aerobic treatment systems to meet expanding production needs [3]. - The company conducted self-monitoring of pollutants, with COD monitored every 2 hours, and ammonia nitrogen monitored quarterly, both within regulatory limits [3]. - The company received environmental credit rating as a "qualified environmental unit" from the Hunan Provincial Ecological Environment Department for 2022 [111]. - The company has established an emergency response plan for environmental incidents, registered with the local environmental authority [108]. Research and Development - Research and development expenses rose by 12.84% to ¥36.81 million, reflecting increased investment in R&D [63]. - The company has established multiple new drug research platforms, including a national-level postdoctoral research workstation and a provincial engineering technology research center [47]. - The company is currently undergoing the drug listing approval process for its innovative traditional Chinese medicine, Nolitong Granules [47]. - The company emphasizes the importance of new product development, acknowledging the high costs and long timelines associated with bringing new drugs to market [80]. Market Position and Strategy - The company completed the acquisition of controlling interest in Fangsheng Tianhong in March 2023, enhancing its market position [7]. - The company has developed a comprehensive marketing system that includes cooperation promotion, general distribution, KA/OTC distribution, and direct supply models to enhance market reach [35]. - The company ranked 63rd in the "2022 Top 100 Chinese Traditional Medicine Enterprises" and was included in the "2022-2023 Top 100 Chinese Pharmaceutical Manufacturing Enterprises" list, indicating significant growth potential [36]. - The company is focusing on cost reduction and efficiency improvement, resulting in a decrease in manufacturing costs and selling expenses [25]. - The company is actively pursuing technology transfers for various pharmaceutical products, with recent transactions valued at 74.20 million yuan and 59.36 million yuan for specific production technologies [78]. Legal Matters - The company reported a total of 255.50 million RMB in litigation liabilities related to contract disputes, with no expected impact on financial performance [135]. - The company is involved in a lawsuit concerning a loan repayment of 69.28 million RMB, which is currently in the execution phase [135]. - A total of 30.54 million RMB is involved in a contract dispute regarding rental payments, which has been settled [135]. - The company has a pending lawsuit involving a claim of 500 million RMB related to a share transfer dispute, which is currently in the execution phase [136]. - The company has reported a total of 203 million RMB in litigation liabilities from investment contract disputes, with the court ruling in favor of the company [136].

湖南方盛制药股份有限公司 HUNANFANGSHENG PHARMACEUTICAL CO., LTD. 证券代码：603998 证券简称：方盛制药 公告编号：2023-072 湖南方盛制药股份有限公司 关于召开 2023 年半年度业绩说明会的公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述或者重 大遗漏，并对其内容的真实性、准确性和完整性承担法律责任。 重要内容提示： 会议召开时间：2023年9月18日(星期一)下午15:00-16:00 会 议 召 开 地 点 ： 上 海 证 券 交 易 所 上 证 路 演 中 心 （ 网 址 ： http://roadshow.sseinfo.com/） 会议召开方式：上证路演中心网络互动 投资者可于2023年9月11日(星期一)至9月15日(星期五)16:00前登录上证路演 中心网站首页点击"提问预征集"栏目或通过公司邮箱：fs88997135@126.com、 603998@fangsheng.com.cn进行提问。公司将在说明会上对投资者普遍关注的问题进行 回答。 湖南方盛制药股份有限公司（以下简称"公司"）已于 2023 年 8 月 31 ...

Financial Performance - The company's operating revenue for Q1 2023 was CNY 436,759,573.82, representing a year-on-year increase of 3.30%[3] - Net profit attributable to shareholders was CNY 63,786,808.29, showing a significant increase of 86.45% compared to the same period last year[3] - The net profit attributable to shareholders after deducting non-recurring gains and losses reached CNY 49,170,758.24, up by 100.58% year-on-year[3] - Basic earnings per share for the period was CNY 0.15, reflecting an increase of 88.21% compared to the previous year[3] - The weighted average return on equity was 4.49%, an increase of 1.67 percentage points year-on-year[3] - Total operating revenue for Q1 2023 was CNY 436,759,573.82, an increase of 3.9% compared to CNY 422,803,032.95 in Q1 2022[20] - Net profit for Q1 2023 was CNY 63,037,123.91, up 100.5% from CNY 31,343,677.50 in Q1 2022[22] - Earnings per share for Q1 2023 were CNY 0.15, compared to CNY 0.08 in Q1 2022, representing an increase of 87.5%[22] - The company reported a profit before tax of CNY 72,299,752.37, compared to CNY 35,808,330.41 in Q1 2022, an increase of 101.3%[21] Assets and Liabilities - Total assets at the end of the reporting period were CNY 2,983,131,860.61, up 2.09% from the end of the previous year[3] - As of March 31, 2023, the total assets of the company amounted to RMB 2,983,131,860.61, an increase from RMB 2,922,150,136.69 at the end of 2022, reflecting a growth of approximately 2.1%[16] - The company reported a total current liabilities of RMB 952,615,299.33, a decrease from RMB 999,587,401.38, reflecting a reduction of about 4.7%[17] - The company’s total liabilities decreased to RMB 1,255,466,225.60 from RMB 1,297,444,234.03, reflecting a decline of about 3.2%[17] - The total liabilities amounted to CNY 1,392,481,793.06, a slight decrease from CNY 1,414,201,204.10 in the previous year[18] Cash Flow - The company reported a net cash flow from operating activities of -CNY 63,977,691.55, indicating a shift from positive to negative cash flow[3] - Cash inflow from operating activities totaled CNY 378,269,536.20, down from CNY 477,571,424.27 in the previous year, a decrease of 20.8%[24] - The net cash flow from operating activities was -$63.98 million, a decrease from $39.25 million in the previous period[25] - Total cash outflow from operating activities amounted to $442.25 million, slightly up from $438.32 million year-over-year[25] - Cash inflow from investment activities totaled $47.96 million, down from $78.08 million in the previous period[25] - The net cash flow from investment activities was -$55.05 million, compared to -$35.46 million in the previous period[25] - Cash inflow from financing activities was $84.33 million, a decrease from $126.35 million year-over-year[25] - The net cash flow from financing activities was -$79.61 million, compared to a positive $19.10 million in the previous period[25] - The ending cash and cash equivalents balance was $184.79 million, down from $279.62 million in the previous period[25] Equity and Investments - Shareholders' equity attributable to the parent company increased to CNY 1,459,415,824.17, a rise of 4.98% from the previous year[3] - Total equity attributable to shareholders increased to CNY 1,459,415,824.17 from CNY 1,390,129,348.50, reflecting a growth of 5.0%[18] - The company’s long-term equity investments increased to RMB 256,735,406.63 from RMB 252,067,896.85, showing a growth of approximately 1.1%[17] - The company’s goodwill rose to RMB 273,983,187.99 from RMB 246,437,637.43, representing an increase of about 11.2%[17] Operational Changes - The increase in net profit was attributed to enhanced product marketing and academic promotion efforts, with the pharmaceutical sector achieving a revenue growth of 22.63%[5] - The company plans to continue focusing on its "338 major product development plan" to drive further growth and efficiency improvements[5] - The company established a new subsidiary, Guangdong Jida Gene Drug Engineering Research Center Co., Ltd., with a registered capital of RMB 7.3 million, holding a 73% equity stake[12] Costs and Expenses - Total operating costs decreased to CNY 383,173,514.19 from CNY 396,051,045.50, reflecting a reduction of approximately 3.5%[20] - Research and development expenses increased to CNY 17,590,859.46 from CNY 16,913,581.31, indicating a growth of 4.0%[21] - The company paid $76.40 million in employee-related cash payments, compared to $99.56 million in the previous period[25] - The company reported a total tax payment of $59.04 million, an increase from $42.57 million year-over-year[25] - Cash outflow for the acquisition of fixed assets was $55.45 million, up from $40.26 million in the previous period[25]

湖南方盛制药股份有限公司 HUNANFANGSHENG PHARMACEUTICAL CO., LTD. 会 议 召 开 地 点 ： 上 海 证 券 交 易 所 上 证 路 演 中 心 （ 网 址 ： http://roadshow.sseinfo.com）； 会议召开方式：上证路演中心网络互动； 证券代码：603998 证券简称：方盛制药 公告编号：2023-042 湖南方盛制药股份有限公司 关于召开2022年度业绩暨现金分红说明会的公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述 或者重大遗漏，并对其内容的真实性、准确性和完整性承担法律责任。 重要内容提示： 会议召开时间：2023 年 5 月 17 日（星期三）下午 16:00—17:00； 第 1 页，共 2 页 投资者可于 2023 年 5 月 10 日（星期三）至 5 月 16 日（星期二）16:00 前登录上 证路演中心网站首页点击"提问预征集"栏目或通过公司邮箱 fs88997135@126.com， 603998@fangsheng.com.cn 进行提问。公司将在说明会上对投资者普遍关注的问题进行回 答。 湖南方盛制 ...

Financial Performance - The company's operating revenue for 2022 was RMB 1,792,000,925.51, representing a 14.36% increase from RMB 1,566,972,727.99 in 2021 [25]. - Net profit attributable to shareholders for 2022 was RMB 285,851,485.43, a significant increase of 308.12% compared to RMB 70,040,562.22 in 2021 [26]. - The basic earnings per share for 2022 was RMB 0.66, reflecting a 312.50% increase from RMB 0.16 in 2021 [27]. - The total assets at the end of 2022 amounted to RMB 2,922,150,136.69, an 8.05% increase from RMB 2,704,474,688.10 at the end of 2021 [26]. - The net cash flow from operating activities for 2022 was RMB 301,625,891.42, which is a 62.49% increase from RMB 185,626,591.50 in 2021 [26]. - The weighted average return on equity for 2022 was 19.24%, up from 5.98% in 2021, indicating a significant improvement [27]. - The net profit after deducting non-recurring gains and losses for 2022 was RMB 106,519,926.79, a 69.03% increase from RMB 63,020,050.07 in 2021 [26]. - The company's net assets attributable to shareholders at the end of 2022 were RMB 1,390,129,348.50, a 16.23% increase from RMB 1,196,044,862.87 at the end of 2021 [26]. Dividend and Shareholder Returns - The board approved a cash dividend of 2.60 CNY per 10 shares for all shareholders, subject to shareholder meeting approval [5]. Audit and Compliance - The financial report was audited and received a standard unqualified opinion from the accounting firm [4]. - The company has not reported any significant differences in governance compared to regulations set by the China Securities Regulatory Commission [167]. - The company has not reported any related party transactions that could affect its independence [167]. Market Strategy and Growth - The company plans to continue expanding its market presence and investing in new product development to sustain growth [27]. - The company aims to enhance its core competitiveness through innovation in traditional Chinese medicine and management transformation [71]. - The company is actively pursuing market expansion through the establishment of new subsidiaries and related transactions [188]. - The company plans to enhance academic promotion and terminal coverage for its pediatric product, Xiaoer Jingxing Cough Granules, to boost sales growth [60]. - The company aims to develop 3 products with a revenue of 1 billion, 3 products with 500 million, and 8 products exceeding 100 million within the next 5-10 years as part of the "338 Major Product Development Plan" [150]. Research and Development - The company has established an Innovation Research Institute to enhance R&D capabilities, focusing on a multi-center development model for innovative traditional Chinese medicine [151]. - The company focuses on the research and development of traditional Chinese medicine and has developed several brand series, including "Xinxuean" for cardiovascular diseases and "Jinbeibei" for pediatrics [71]. - The company has 141 drug registration certificates and 17 new drug certificates, indicating a strong product reserve to support strategic goals [72]. - The company is actively involved in various clinical trials, including the ongoing clinical research for the pediatric cough granules and the application review for Nolitong granules [134]. Operational Efficiency - The company has successfully reduced production costs for key raw materials, enhancing overall profitability and operational efficiency [37]. - The company has implemented a comprehensive safety management system, achieving a 100% safety hazard rectification rate and no major safety incidents during the reporting period [43]. - The company has initiated a group management enhancement project to optimize organizational structure and improve operational efficiency [44]. Employee Management and Development - The company has focused on talent acquisition and training, establishing a performance-based incentive system to enhance employee engagement and loyalty [45]. - The company emphasizes a performance-oriented "three-dimensional" incentive system to enhance employee motivation and align with long-term development goals [199]. - Comprehensive training programs are provided to support employees' career development and skill enhancement [200]. Industry Trends and Market Conditions - The pharmaceutical industry in China continues to grow, supported by government policies promoting research and innovation, with a strong emphasis on traditional Chinese medicine [46]. - The total revenue of the top 100 pharmaceutical companies in China reached CNY 1,076.2 billion in 2021, marking a year-on-year growth of 19.40% [52]. - The market for pediatric traditional Chinese medicine (TCM) has shown stable growth, with a terminal sales scale of 10.4 billion RMB in 2021, a 43% increase from 2015 [58]. Financial Management - The company reported a significant increase in contract liabilities, which rose by 149.26% to ¥87.45 million, mainly due to pre-receipts from customers [110]. - The company’s total liabilities decreased by 52.60% to ¥210.25 million, reflecting a strategic adjustment in its borrowing structure [110]. - The company has made provisions for asset impairment and bad debt reserves in its financial reports [186]. Governance and Board Activities - The company conducted 16 board meetings and 13 supervisory meetings during the reporting period, ensuring compliance with legal and regulatory requirements [163][164]. - The company held a total of 3 shareholder meetings during the reporting period, with all proposed resolutions approved [169]. - The company has undergone changes in its board composition, with several members resigning and new members being elected [183]. Future Outlook - Future outlook indicates a projected revenue growth of 15% for the next fiscal year, driven by new product launches and market expansion strategies [173]. - The company anticipates a recovery in the pharmaceutical industry, driven by ongoing reforms and policy support, indicating a positive outlook for growth in the sector [148].

2022-001 证券代码：603998 证券简称：方盛制药 湖南方盛制药股份有限公司 投资者关系活动记录表 编号： | --- | --- | --- | |-----------------------|------------------------------|--------------------------------------------------------------| | | 特定对象调研 | 分析师会议 | | | 媒体采访 | 业绩说明会 | | 投资者关系活动 | 新闻发布会 | 路演活动 | | 类别 | 现场参观 | 电话会议 | | | 其他 | | | 参与单位名称 | | | | （排名不分先 | | 华安证券、瀚伦投资、永赢基金、红土创新、长安基金 | | 后） | | | | 时间 2022 | 年 4 月 29 | 日 14:00-15:00 | | | 地点 公司会议室 | | | 会议形式 电话会议 | | | | 上市公司接待人 员姓名 | | 董事会秘书何仕、证券事务代表曾博茹 | | | 主要交流内容： | | | | | 一、公司业务情况介绍 | | ...

证券代码：603998 证券简称：方盛制 药 湖南方盛制药股份有限公司 投资者关系活动记录表 编号： 2022-002 | --- | --- | --- | |-------------------|----------------------|------------------------------------------------------------| | | 特定对象调研 | 分析师会议 | | | 媒体采访 | 业绩说明会 | | 投资者关系活动 | 新闻发布会 | 路演活动 | | 类别 | 现场参观 | 电话会议 | | | 其他 | | | | | 华鑫证券、富唐资产、诺德基金、金百镕投资、天弘基金、君和资 | | 参与单位名称 | | 本、嘉合基金、上海天猊投资、中新融创、中科沃土、中原英石基 | | （排名不分先 | | 金、国海富兰克林、华宝信托、南方睿泰基金、理成资产、上海国 | | 后） | 际信托、泰康资产等 | | | 时间 2022 | 年 5 月 5 日 | 10:30-11:30 | | | 地点 公司会议室 | | | 会议形式 电话会议 | | | | 上市公 ...

证券代码：603998 证券简称：方盛制药 编号：2022-004 湖南方盛制药股份有限公司 投资者关系活动记录表 | --- | --- | --- | |-----------------------|--------------------------------------------------------------------|---------------------------------------------------------------------------------------------------------------------| | 投资者关系活动 \n类别 | 特定对象调研 \n 媒体采访 \n 新闻发布会 \n 现场参观 \n 其他 | 分析师会议 \n 业绩说明会 \n 路演活动 \n 电话会议 | | 参与单位名称 | 华鑫证券俞家宁 | | | 时间 2022 | 年 6 月 1 日 | 15:00-17:30 | | | 地点 公司会议室 | | | 会议形式 现场调研 | | | | 上市公司接待人 员姓名 | 董事会秘书何仕 | | | | 主要交 ...